Clinical Trial Update: Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen® [Phase 2, Phase 3]

View source ↗

Summary

An adaptive Phase II/III trial of NaBen for schizophrenia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• NaBen

Snippet

Sponsor: SyneuRx International (Taiwan) Corp | Conditions: Schizophrenia | Phase 2, Phase 3 | Status: TERMINATED